Amphion Innovations plc

Order Dismissing DataTern Case

London and New York, 2 November 2017 - Amphion Innovations plc (AIM: AMP), the developer of medical, life science, and technology businesses, announces that on 20 October 2017 the case brought by DataTern Inc. (“DataTern”), a wholly-owned subsidiary of Amphion, against MicroStrategy Inc. and certain of its customers was dismissed.

The reason for the case dismissal was the withdrawal of DataTern’s legal counsel and the inability of DataTern to identify and appoint a successor counsel in the short time frame set by the Court.

It remains DataTern’s considered opinion that the 502 and 402 patents are both valid and being infringed by a wide range of companies that are practicing this critical art. In order to pursue these claims though, DataTern needs to be able to fund the expenses in the programme and efforts to find a suitable funding source and successor legal counsel are continuing.


For further information please contact

Amphion Innovations
Charlie Morgan
+1 212 210 6224

Panmure Gordon Limited (Nominated Adviser and Corporate Broker)
Freddy Crossley / Duncan Monteith (Corporate Finance)
Charlie Leigh-Pemberton (Corporate Broking)
+44 (0)20 7886 2500

Northland Capital Partners Limited (Joint Corporate Broker)
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Mark Treharne (Corporate Broking)
+44 (0)20 3861 6600

Walbrook PR
Mike Wort / Paul McManus
+44 (0)20 7933 8780

About Amphion Innovations plc
Amphion Innovations is a developer of medical, life science and technology businesses.

We use our extensive experience in company building to invest and build shareholder value in high growth companies in the US and UK. Amphion has significant shareholding in a small number of Partner Companies developing proven technologies targeting substantial commercial marketplaces. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies.